Plx-4032 (RG7024)

Plx-4032 (RG7024) Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: 571-85586718 +8613336195806
Email: sales@capotchem.com
Products Intro: Product Name:PLX-4032
CAS:1029872-54-5
Purity:98%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd
Tel: 010-60279497
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:Vemurafenib
CAS:1029872-54-5
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: career henan chemical co
Tel: +86-0371-86658258
Email: sales@coreychem.com
Products Intro: Product Name:Plx-4032 (RG7024)
CAS:1029872-54-5
Purity:99% Package:1KG;1USD
Company Name: Chongqing Chemdad Co., Ltd
Tel: +86-023-61398051 +8613650506873
Email: sales@chemdad.com
Products Intro: Product Name:Plx-4032 (RG7024)
CAS:1029872-54-5
Purity:0.98 Package:1kg,2kg,5kg,10kg,25kg
Company Name: Shaanxi Dideu Medichem Co. Ltd
Tel: +86-29-87569266 15319487004
Email: 1015@dideu.com
Products Intro: Product Name:Vemurafenib
CAS:1029872-54-5
Purity:99.0% Package:100g;1kg;5kg;25kg

Plx-4032 (RG7024) manufacturers

  • Plx-4032 (RG7024)
  • Plx-4032 (RG7024) pictures
  • $15.00 / 1KG
  • 2021-07-02
  • CAS:1029872-54-5
  • Min. Order: 1KG
  • Purity: 99%+ HPLC
  • Supply Ability: Monthly supply of 1 ton
  • Vemurafenib
  • Vemurafenib pictures
  • $0.00 / 1KG
  • 2020-04-30
  • CAS:1029872-54-5
  • Min. Order: 1KG
  • Purity: 99.0%+
  • Supply Ability: 800 tons
Plx-4032 (RG7024) Basic information
Product Name:Plx-4032 (RG7024)
Synonyms:Plx-4032 (RG7024);PLX 4032; RG 7204; RO 5185426;RG 7204;RO 5185426;N-[3-[[5-(4-Chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-PropanesulfonaMide;N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonaMide;VeMurafenib,PLX 4032;1-PropanesulfonaMide, N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-
CAS:1029872-54-5
MF:C23H18ClF2N3O3S
MW:489.9221264
EINECS:800-227-2
Product Categories:
Mol File:1029872-54-5.mol
Plx-4032 (RG7024) Structure
Plx-4032 (RG7024) Chemical Properties
Melting point >263oC (dec.)
storage temp. Refrigerator
solubility DMSO (Slightly, Heated), Methanol (Slightly, Heated)
form Solid
color Off-White
CAS DataBase Reference1029872-54-5
Safety Information
MSDS Information
Plx-4032 (RG7024) Usage And Synthesis
UsesVemurafenib selective BRAFV600E kinase inhibitor; an antitumor agent. Vemurafenib functions by inhibiting the proliferation and mitogen-activated protein/extracellular signal-regulated kinase (ERK) kinase and ERK phosphorylation in a panel of tumor cell lines, including melanoma cell lines expressing BRAFV600E or other mutant BRAF proteins altered at codon 600. Potent B-Raf inhibitor
DefinitionChEBI: Vemurafenib is a pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases. It has a role as an antineoplastic agent and a B-Raf inhibitor. It is a pyrrolopyridine, a sulfonamide, a member of monochlorobenzenes, a difluorobenzene and an aromatic ketone.
Clinical UseVemurafenib was originally discovered at Plexxikon and has been co-developed by Roche and Plexxikon as an oral BRAF inhibitor for the treatment of patients with BRAFV600E mutation- positive metastatic melanoma. The drug displays good potency and selectivity for the V600E mutation (IC50 = 3.2–14 nM), an oncoprotein, over the wild-type BRAF (IC50 = 21–370 nM). The compound is less potent in in vitro kinase assays than other Plexxikon BRAF inhibitors, but it was selected for clinical development based on its enhanced potency against the BARFV600E-containing A374 melanoma cell line.
SynthesisThe synthesis described below is based on a recent process patent (the Scheme).

Synthesis_1029872-54-5


Commercially available 2-amino-5-bromopyridine (271) was treated with 4-chlorophenylboronic acid (272) in the presence of Na2CO3 and a catalytic amount of Pd(OAc)2/PdCl2(dppf)CH2Cl2 to give Suzuki product 273 in 83% yield. Arene 273 was subjected to iodination conditions using NIS and TFA to provide iodide 274 in 98% yield. Iodide 274 and pinacol vinylboronate 275 were coupled under Suzuki conditions followed by treatment with acid to affect a tandem coupling¨Ccyclization sequence which resulted in pyrimidyl pyrrole 276 in good yield. This material was treated with aluminum trichloride and then subjected to the the acyl chloride of commercially available sulfonamide acid 277, triggering a Friedel- Crafts reaction providing vemurafenib (XXIV) in 85% yield.
Drug interactionsPotentially hazardous interactions with other drugs
Anticoagulants: possibly enhances anticoagulant effect of warfarin.
Antipsychotics: avoid concomitant use with clozapine, risk of agranulocytosis.
Oestrogens and progestogens: contraceptive effect possibly reduced.
MetabolismOnly 5
% of a dose of vemurafenib is metabolised. 94
% of the dose is excreted in the faeces and 1
% in the urine.
Plx-4032 (RG7024) Preparation Products And Raw materials
Tag:Plx-4032 (RG7024)(1029872-54-5) Related Product Information
PLX4032 2-Chloro-N-[4-chloro-3-(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide Cabozantinib Nintedanib Bosutinib Alectinib Afatinib Palbociclib Nilotinib Dasatinib Dabrafenib XL518 Regorafenib Ponatinib Ibrutinib Lenvatinib Crizotinib Tofacitinib